These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 31623592)
1. Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer. Advani SM; Advani PS; Brown DW; DeSantis SM; Korphaisarn K; VonVille HM; Bressler J; Lopez DS; Davis JS; Daniel CR; Sarshekeh AM; Braithwaite D; Swartz MD; Kopetz S BMC Cancer; 2019 Oct; 19(1):964. PubMed ID: 31623592 [TBL] [Abstract][Full Text] [Related]
2. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637 [TBL] [Abstract][Full Text] [Related]
3. Epidemiology and Molecular-Pathologic Characteristics of CpG Island Methylator Phenotype (CIMP) in Colorectal Cancer. Advani SM; Swartz MD; Loree J; Davis JS; Sarsashek AM; Lam M; Lee MS; Bressler J; Lopez DS; Daniel CR; Morris V; Shureqi I; Kee B; Dasari A; Vilar E; Overman M; Hamilton S; Maru D; Braithwaite D; Kopetz S Clin Colorectal Cancer; 2021 Jun; 20(2):137-147.e1. PubMed ID: 33229221 [TBL] [Abstract][Full Text] [Related]
4. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling. Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224 [TBL] [Abstract][Full Text] [Related]
5. Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Ogino S; Kawasaki T; Kirkner GJ; Suemoto Y; Meyerhardt JA; Fuchs CS Gut; 2007 Nov; 56(11):1564-71. PubMed ID: 17339237 [TBL] [Abstract][Full Text] [Related]
6. Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers? Bae JM; Rhee YY; Kim KJ; Wen X; Song YS; Cho NY; Kim JH; Kang GH Hum Pathol; 2016 Jan; 47(1):85-94. PubMed ID: 26520418 [TBL] [Abstract][Full Text] [Related]
7. CpG island methylator phenotype and prognosis of colorectal cancer in Northeast China. Li X; Hu F; Wang Y; Yao X; Zhang Z; Wang F; Sun G; Cui BB; Dong X; Zhao Y Biomed Res Int; 2014; 2014():236361. PubMed ID: 25243122 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Juo YY; Johnston FM; Zhang DY; Juo HH; Wang H; Pappou EP; Yu T; Easwaran H; Baylin S; van Engeland M; Ahuja N Ann Oncol; 2014 Dec; 25(12):2314-2327. PubMed ID: 24718889 [TBL] [Abstract][Full Text] [Related]
9. Prognostic value of CpG island methylator phenotype among hepatocellular carcinoma patients: A systematic review and meta-analysis. Wang Q; Wang G; Liu C; He X Int J Surg; 2018 Jun; 54(Pt A):92-99. PubMed ID: 29698791 [TBL] [Abstract][Full Text] [Related]
10. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway. Kim JH; Bae JM; Cho NY; Kang GH Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113 [TBL] [Abstract][Full Text] [Related]
11. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942 [TBL] [Abstract][Full Text] [Related]
12. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype. Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252 [TBL] [Abstract][Full Text] [Related]
13. Different definitions of CpG island methylator phenotype and outcomes of colorectal cancer: a systematic review. Jia M; Gao X; Zhang Y; Hoffmeister M; Brenner H Clin Epigenetics; 2016; 8():25. PubMed ID: 26941852 [TBL] [Abstract][Full Text] [Related]
14. Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma. Ogino S; Odze RD; Kawasaki T; Brahmandam M; Kirkner GJ; Laird PW; Loda M; Fuchs CS Am J Surg Pathol; 2006 Sep; 30(9):1175-83. PubMed ID: 16931963 [TBL] [Abstract][Full Text] [Related]
15. Epigenetic insights into colorectal cancer: comprehensive genome-wide DNA methylation profiling of 294 patients in Korea. Joe S; Kim J; Lee JY; Jeon J; Byeon I; Han SW; Ryoo SB; Park KJ; Song SH; Cho S; Shim H; Bao Khanh Chu H; Kang J; Lee HS; Kim D; Kim YJ; Kim TY; Kim SY BMB Rep; 2023 Oct; 56(10):563-568. PubMed ID: 37574809 [TBL] [Abstract][Full Text] [Related]
16. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478 [TBL] [Abstract][Full Text] [Related]
17. CpG island methylator phenotype is an independent predictor of survival after curative resection for colorectal cancer: A prospective cohort study. Kim CH; Huh JW; Kim HR; Kim YJ J Gastroenterol Hepatol; 2017 Aug; 32(8):1469-1474. PubMed ID: 28087988 [TBL] [Abstract][Full Text] [Related]
18. TGFBR2 mutation is correlated with CpG island methylator phenotype in microsatellite instability-high colorectal cancer. Ogino S; Kawasaki T; Ogawa A; Kirkner GJ; Loda M; Fuchs CS Hum Pathol; 2007 Apr; 38(4):614-20. PubMed ID: 17270239 [TBL] [Abstract][Full Text] [Related]
19. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype. Toyota M; Ohe-Toyota M; Ahuja N; Issa JP Proc Natl Acad Sci U S A; 2000 Jan; 97(2):710-5. PubMed ID: 10639144 [TBL] [Abstract][Full Text] [Related]
20. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Overman MJ; Adam L; Raghav K; Wang J; Kee B; Fogelman D; Eng C; Vilar E; Shroff R; Dasari A; Wolff R; Morris J; Karunasena E; Pisanic TR; Azad N; Kopetz S Ann Oncol; 2018 Jan; 29(1):139-144. PubMed ID: 29069279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]